Cargando…
Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia
Acute Myeloid Leukemia (AML) is an aggressive myeloid malignancy associated with high mortality rates (less than 30% 5-year survival). Despite advances in our understanding of the molecular mechanisms underpinning leukemogenesis, standard-of-care therapeutic approaches have not changed over the last...
Autores principales: | Schorr, Christopher, Perna, Fabiana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809466/ https://www.ncbi.nlm.nih.gov/pubmed/36605213 http://dx.doi.org/10.3389/fimmu.2022.1085978 |
Ejemplares similares
-
Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies
por: Schorr, Christopher, et al.
Publicado: (2023) -
Chimeric antigen receptor T-cell therapy in acute myeloid leukemia
por: Koedam, Jan, et al.
Publicado: (2022) -
Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
por: Driouk, Lina, et al.
Publicado: (2020) -
Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis
por: Shahzad, Moazzam, et al.
Publicado: (2023) -
Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
por: Fan, Mingxue, et al.
Publicado: (2017)